about
Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damageNon-invasive assessment of liver fibrosis in patients with alcoholic liver disease.Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countriesNon-invasive diagnosis of liver fibrosis in chronic hepatitis CExpanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDSHGF and direct mesenchymal stem cells contact synergize to inhibit hepatic stellate cells activation through TLR4/NF-kB pathwayEfficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settingsSystems level analysis and identification of pathways and networks associated with liver fibrosisCystic fibrosis related liver disease--another black box in hepatology.Cirrhosis and other liver disease in cystic fibrosis.Noninvasive Markers of Fibrosis and Inflammation in Nonalcoholic Fatty Liver Disease.The effect of applied transducer force on acoustic radiation force impulse quantification within the left lobe of the liver.Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions.Egy-score predicts severe hepatic fibrosis and cirrhosis in Egyptians with chronic liver diseases: a pilot study.Increased liver stiffness denotes hepatic dysfunction and mortality risk in critically ill non-cirrhotic patients at a medical ICULiver disease as a cause of thrombocytopenia.Value of MR diffusion imaging in hepatic fibrosis and its correlations with serum indices.Alpha-fetoprotein level as a biomarker of liver fibrosis status: a cross-sectional study of 619 consecutive patients with chronic hepatitis B.Serum proteome profiling identifies novel and powerful markers of cystic fibrosis liver diseaseWillingness to undergo a repeat liver biopsy among HIV/hepatitis C virus-coinfected and hepatitis C virus-monoinfected patients.Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients.The N-terminal propeptide of type III procollagen in patients with acute coronary syndrome: a link between left ventricular end-diastolic pressure and cardiovascular events.Diagnostic accuracy of noninvasive markers of liver fibrosis in patients with psoriasis taking methotrexate: a systematic review and meta-analysis.Lymphocytes as liver damage mirror of HCV related adipogenesis deregulation.Turnover rates of hepatic collagen and circulating collagen-associated proteins in humans with chronic liver diseaseAspartate aminotransferase to platelet ratio index as a prospective predictor of hepatocellular carcinoma risk in patients with chronic hepatitis B virus infectionQuantification of liver fibrosis via second harmonic imaging of the Glisson's capsule from liver surface.The promise of metabolic phenotyping in gastroenterology and hepatology.Metabolic Characterization of Advanced Liver Fibrosis in HCV Patients as Studied by Serum 1H-NMR SpectroscopyMolecular MR imaging of liver fibrosis: a feasibility study using rat and mouse models.Serum Levels of Annexin A2 as a Candidate Biomarker for Hepatic Fibrosis in Patients With Chronic Hepatitis B.Obstructive sleep apnea and non-alcoholic Fatty liver disease: is the liver another target?Aspartate transaminase to platelet ratio index in hepatitis C virus and Schistosomiasis coinfection.Enteral autonomy, cirrhosis, and long term transplant-free survival in pediatric intestinal failure patients.FibroScan, aspartate aminotransferase and alanine aminotransferase ratio (AAR), aspartate aminotransferase to platelet ratio index (APRI), fibrosis index based on the 4 factor (FIB-4), and their combinations in the assessment of liver fibrosis in paKnowledge-based identification of soluble biomarkers: hepatic fibrosis in NAFLD as an exampleThe new paradigm of hepatitis C therapy: integration of oral therapies into best practices.Ultrasound shear wave elastography and liver fibrosis: A Prospective Multicenter Study.Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension.Serum biomarkers in nonalcoholic steatohepatitis: value for assessing drug effects?
P2860
Q26773289-703617EC-F204-43B9-97EC-7B5A6FE91657Q26780258-196E84F2-AF79-4C09-A78C-84F2A270AC60Q26828855-86E69F67-541C-4BD0-AD7E-23A94EA4A921Q26865956-D667D9C8-F08A-4B78-81F9-4385EC10373CQ27004509-005FE2BB-201C-4D23-888C-857EC88DE057Q28482499-F060EC25-406A-466A-A3EF-D387AE6FC4E9Q28540372-18A87927-4618-44FC-9F81-FF4263E7CCB7Q28544814-61A9FD96-2C2A-43F6-B8F5-15DB97574896Q28655881-9A5EC3E8-1BE7-42A6-A2A6-F1FB953F9CADQ28660820-3FD6EDEA-2EB5-4B83-B29D-FC0E02E74E42Q30355082-CE2CC7F5-9EDC-452E-BFE0-EEFE5B7F1558Q30363451-60B45758-C6A9-4249-8353-7666B81E309BQ30397191-5F6C1FC3-5619-4A61-8CF6-E22FB26FD7F8Q30449245-B69D0DE9-B610-47DB-8611-6F9CCA29BD5BQ30465982-60BCA9A3-658E-4119-8243-8DA6E0EEC979Q33405472-0B947FC1-F12A-4188-9116-EA3C0400E627Q33801435-6A0D1D0F-0283-4559-9366-57628E2FDA10Q34071329-1C85CBC9-6414-46CF-8CDF-4F0D4C1BB49DQ34630224-7E2AE848-5FE8-4BB4-BF41-A2814AF9EEB4Q34670502-E05DDCE2-D5F1-4BFA-B208-E061E163CBD8Q34684406-02082247-EEF5-48DB-818C-6B8DD0AC9236Q34822562-8C9CF955-638D-49CF-8848-109820843879Q35109287-79A58472-F38A-4877-BEAB-3FD8CA020200Q35128041-0D388736-EF03-4622-8CFF-13F4F37C8709Q35536468-6A49A03C-152D-4659-B22C-667C6BB7E0ACQ35565542-DEB47BD8-F4F7-4CE2-AFE6-E07247A69B56Q35679627-95118EA2-2C31-4E43-9AD1-C89AC09E0CFAQ35701279-FCE19806-5153-4221-8027-AD33C4F5D4F6Q36012032-F8762351-E3C0-4D87-AD18-C570B76F0DD1Q36177218-CC51BC87-5A12-49CA-9AE7-50F076BA5A9DQ36279439-20C12E2E-E747-4F84-95C2-35DCC2784B4BQ36323458-361D26CC-1B69-4F6A-B72B-168A3A0E6C09Q36360843-7D6722AA-4536-421C-873A-4A02A6AE1A0BQ36463864-ED73E096-F8DA-4C7B-B7ED-47B2EEFC9614Q36492881-1C7B262D-2645-4373-A57B-978F6C4A315EQ36591980-9CDAB8EE-C5A1-4CAD-AB67-8DE2397A7AF1Q37455611-54918F9A-AD80-4848-BD49-EA12D7A9EAD7Q37570946-E1242603-8729-4D9E-ADF5-F8B6A86B5B10Q37604322-0F04E9D5-5182-4084-8952-FBF080AE4901Q38066240-ED168347-5419-4552-9F08-DE137590D55A
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Non-invasive markers for hepatic fibrosis
@ast
Non-invasive markers for hepatic fibrosis
@en
type
label
Non-invasive markers for hepatic fibrosis
@ast
Non-invasive markers for hepatic fibrosis
@en
prefLabel
Non-invasive markers for hepatic fibrosis
@ast
Non-invasive markers for hepatic fibrosis
@en
P2093
P2860
P356
P1433
P1476
Non-invasive markers for hepatic fibrosis
@en
P2093
Ancha Baranova
Aybike Birerdinc
Priyanka Lal
Zobair M Younossi
P2860
P2888
P356
10.1186/1471-230X-11-91
P5008
P577
2011-08-17T00:00:00Z
P6179
1018461702